BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

984 related articles for article (PubMed ID: 15665303)

  • 1. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
    Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
    Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR; Vega MI; Bonavida B
    Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S; Emmanouilides C; Bonavida B
    Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
    Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
    Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S; Ng CP; Bonavida B
    Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B
    Oncogene; 2007 May; 26(25):3629-36. PubMed ID: 17530016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.
    Aggarwal S; Ichikawa H; Takada Y; Sandur SK; Shishodia S; Aggarwal BB
    Mol Pharmacol; 2006 Jan; 69(1):195-206. PubMed ID: 16219905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.
    Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B
    Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB.
    Kasof GM; Lu JJ; Liu D; Speer B; Mongan KN; Gomes BC; Lorenzi MV
    Oncogene; 2001 Nov; 20(55):7965-75. PubMed ID: 11753679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB.
    Schmelz K; Wieder T; Tamm I; Müller A; Essmann F; Geilen CC; Schulze-Osthoff K; Dörken B; Daniel PT
    Oncogene; 2004 Sep; 23(40):6743-59. PubMed ID: 15273737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S; Vega M; Garban H; Bonavida B
    Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
    Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
    Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.